A simplified assay for measurement of cytosine arabinoside incorporation into DNA in Ara-C-sensitive and -resistant leukemic cells
- PMID: 2249332
- DOI: 10.1007/BF00689101
A simplified assay for measurement of cytosine arabinoside incorporation into DNA in Ara-C-sensitive and -resistant leukemic cells
Abstract
The assays for the detection of unlabeled 1-beta-D-arabinofuranosylcytosine (cytosine arabinoside, Ara-C) incorporation into DNA was simplified. The procedure includes DNA isolation from leukemic cells, quantification of DNA concentrations, breakdown by enzymatic digestion of DNA to nucleosides and a radioimmunoassay (RIA) using an antibody against Ara-C. Different techniques for quantification of DNA concentrations are compared. A fluorimetric technique using Hoechst 33258 is preferred because it is the most specific method. Comparison of this RIA assay with measurement of [3H]-Ara-C/DNA formation under similar conditions in HL-60 cells showed a correlation of 0.99. Ara-C incorporation into DNA of leukemic cells was studied using two rat-leukemia cell lines, one of which is sensitive to Ara-C and the other is an Ara-C-resistant wild type: BNML-Cl/0 and BNML-Cl/Ara-C, respectively. The results showed that Ara-C is incorporated when the cells are incubated at concentrations equal to or higher than the Ara-C concentration that induces 50% growth inhibition after 48 h incubation (IC50). This implies that at lower Ara-C concentration, i.e. levels that do not induce cytotoxicity, Ara-C is not incorporated into DNA. Similar results were obtained with human HL-60 myeloid leukemia cells. The detection limit of this assay is 2 pmol/ml Ara-C; therefore, the assay is more sensitive than measurement of Ara-C triphosphate (Ara-CTP), the only metabolite that can be measured in leukemic cells from patients after in vivo Ara-C administration. On the basis of in vitro studies, the finding of detectable Ara-C/DNA levels in vivo is expected to correlate with cytotoxicity; whether or not the Ara-C/DNA level itself is informative remains to be evaluated.
Similar articles
-
Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.Leuk Res. 1996 Feb;20(2):127-34. doi: 10.1016/0145-2126(95)00071-2. Leuk Res. 1996. PMID: 8628011
-
Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo.Cancer Res. 1987 Dec 15;47(24 Pt 1):6532-6. Cancer Res. 1987. PMID: 3479246
-
Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.Semin Oncol. 1992 Apr;19(2 Suppl 4):31-7. Semin Oncol. 1992. PMID: 1553573
-
1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview.Pharmacol Ther. 1992 Dec;56(3):307-21. doi: 10.1016/0163-7258(92)90022-r. Pharmacol Ther. 1992. PMID: 1301593 Review.
-
Cellular and clinical pharmacology of low-dose ara-C.Semin Oncol. 1985 Jun;12(2 Suppl 3):200-7. Semin Oncol. 1985. PMID: 3925558 Review.
Cited by
-
Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway.Ann Hematol. 1992 Jul;65(1):26-32. doi: 10.1007/BF01715122. Ann Hematol. 1992. PMID: 1643157
-
New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase.Pharm World Sci. 1994 Apr 15;16(2):104-12. doi: 10.1007/BF01880661. Pharm World Sci. 1994. PMID: 7980770 Review.
-
Therapeutic drug monitoring of antimetabolic cytotoxic drugs.Br J Clin Pharmacol. 1999 Feb;47(2):131-43. doi: 10.1046/j.1365-2125.1999.00884.x. Br J Clin Pharmacol. 1999. PMID: 10190647 Free PMC article. Review.